Ankylosing spondylitis market forecast with key trends and growth potential

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Ankylosing Spondylitis Market During 2026–2030?

The ankylosing spondylitis market has demonstrated significant expansion in recent years. It is anticipated to increase from $6.34 billion in 2025 to $6.85 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. This historic growth can be attributed to factors such as heightened diagnostic awareness, greater access to NSAIDs and DMARDs, an increase in specialist rheumatology services, wider availability of hospital-based treatment, and the expanding utilization of imaging for monitoring disease.

The ankylosing spondylitis market is anticipated to show significant expansion in the coming years. It is projected to reach $9.42 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.3%. This projected growth can be attributed to the increasing uptake of biologics and biosimilars, a heightened emphasis on personalized medicine, the development of advanced biologic pipelines, a rising demand for comprehensive long-term disease management, and increased funding for autoimmune research. Prominent trends expected during this forecast period involve a broader adoption of biologic therapies, an elevated use of targeted DMARDs, a stronger focus on early disease detection, the broadening of personalized treatment strategies, and a more integrated approach to physical therapy programs.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Which Important Drivers Are Guiding The Ankylosing Spondylitis Market Growth?

The ankylosing spondylitis market is set for growth owing to the escalating occurrence of autoimmune diseases. Autoimmune disorders represent a broad spectrum of conditions where the immune system exhibits an abnormal response, erroneously attacking and causing harm to healthy cells, tissues, and organs within the body. Specifically, conditions like ankylosing spondylitis manifest when the immune system incorrectly targets the body’s own tissues, initiating inflammation and subsequent damage. Both genetic predispositions and environmental elements play a role in the onset of ankylosing spondylitis, which is a type of autoimmune arthritis primarily affecting the spine and pelvis. For instance, in September 2023, the Impact of IBD Report 2023, published by the IBD Clinical and Research Centre (a Canada-based organization focused on enhancing the lives of patients with Crohn’s disease and ulcerative colitis), reported a prevalence of 825 per 100,000 in 2023, indicating that over 320,000 individuals in Canada have inflammatory bowel disease (IBD). With an anticipated annual increase in prevalence of 2.44%, projections suggest that 1.1% of the population, or 470,000 Canadians, will be living with IBD by 2035. Thus, the rising incidence of autoimmune diseases is poised to propel the future expansion of the ankylosing spondylitis market.

How Is The Ankylosing Spondylitis Market Organized By Segment Classification?

The ankylosing spondylitis market covered in this report is segmented –

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery

2) By Molecule: Biologics, Biosimilar, Small Molecules

3) By Route Of Administration: Parenteral, Oral, Other Routes

4) By Application: Juveniles, Adults

5) By End User: Hospitals, Clinics

Subsegments:

1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs

3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors

4) By Steroids: Oral Steroids, Injectable Steroids

5) By Physical Therapies: Physiotherapy, Exercise Programs

6) By Surgery: Joint Replacement Surgery, Spinal Surgery

What Trends Are Influencing The Evolution Of The Ankylosing Spondylitis Market?

Major companies within the ankylosing spondylitis market are focusing on creating advanced biologic solutions, such as biosimilars, to improve patient accessibility, lower treatment expenses, and offer accustomed administration options. These biosimilars are therapeutics that utilize the proven active ingredients of reference biologics while maintaining comparable efficacy and safety characteristics. For instance, in August 2025, Amgen Biotechnology Singapore, a Singapore-based biotech firm, gained approval for its biosimilar adalimumab (Amgevita), offered in both a 40 mg/0.4 mL autoinjector and a 20 mg/0.2 mL prefilled syringe. This particular therapy is indicated for reducing indicators and symptoms in adult patients with active ankylosing spondylitis who have had an inadequate response to standard therapy, thereby providing familiar administration methods, leveraging a recognized active ingredient, and presenting a more affordable alternative in the biologics domain.

Who Are The Industry Participants Involved In The Ankylosing Spondylitis Market?

Major companies operating in the ankylosing spondylitis market are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

Get The Full Ankylosing Spondylitis Market Report:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Which Region Has The Greatest Market Share In The Ankylosing Spondylitis Market?

North America was the largest region in the ankylosing spondylitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Ankylosing Spondylitis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Browse Through More Reports Similar to the Global Ankylosing Spondylitis Market 2026, By The Business Research Company

Osteoarthritis Market Report 2026

https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report

Cervical Spondylosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cervical-spondylosis-treatment-global-market-report

Axial Spondyloarthritis Axspa Market Report 2026

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795